msb targeted as world leader ..

Roadshow in the City - Broadening Mesoblast’s Network of Supporters Within the European Sell-side Circuit

Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY) is the world’s leading developer of innovative biological products for the broad field of regenerative medicine.

The Company’s commercial strategy is based on its unique proprietary adult mesenchymal precursor cells, a type of stem cell which can be used ‘off the shelf’. The Company’s lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.

Albeit well known in Australia, where it is the fourth largest life science company on the stock exchange, College Hill has been retained to broaden its profile in Europe with the financial and life science business communities. We have been doing this through a comprehensive media and analyst relations program.

Objectives
To select the leading banks in the City of London with an interest in the life science industry and stimulate interest in Mesoblast.
To organise and sit-in on meetings between the Company and the relevant sell-side analyst to ensure they ran smoothly and all topics (to sell the Company optimally) were covered.

Our Approach
We worked with Mesoblast's CFO, Graeme Kaufman to establish which institutions he knew either in London or in Australia and the US.
We put together a target list of institutions for approval by Mesoblast.
Once approved, we sent an invitation around to the targets with a brief description of the Company and its most recent press releases.
We organised the logistics of the meetings to ensure most efficient use of time.
We liaised with the Bell Potter team who were organising buy-side meetings later in the week.
We attended the majority of the meetings to ensure they went smoothly and all topics were covered.
After the roadshow was completed, we followed up with each analyst and produced a summary of comments for the Client.
We intend to do this again to ensure we reach the rest of the targets on our analyst list, next time the Company management is in London.

Results

In total, eight meetings were organised over two days with the following leading international investment banks in London:
BoA Merrill Lynch
Edison Investment Research
Goldman Sachs
Jefferies
Morgan Stanley
Peel Hunt
Religare
UBS

The response to Mesoblast and to the way Graeme presented the story was very positive. Overall, analysts were very interested and impressed by the business model.

In the words of one analyst: “I thought this was a really great company – really, really, really interesting. It’s a shame it’s not listed in the UK. Mesoblast represents a real paradigm shift in the sector and I see it as a ‘trailblazer’. We think this area of medicine is very important for the future.”
.....Cheers Vin